Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcεR1 expression level and omalizumab clinical response.

"CONFLICTS OF INTEREST STATEMENT Ana M. Giménez‐Arnau: Medical Advisor for Uriach Pharma/Neucor, Genentech, Novartis, FAES, GSK, Sanofi–Regeneron, Amgen, Thermo Fisher Scientific, Almirall, Celldex, Leo Pharma Research Grants supported by Uriach Pharma, Novartis, Grants from Instituto Carlos III‐FEDER Educational activities for Uriach Pharma, Novartis, Genentech, Menarini, LEO‐PHARMA, GSK, MSD, Almirall, Sanofi, Avene. Bruno Cenni and Barbara Ambros are Novartis employees. The rest of authors declare that there is no conflict of interest concerning the present work."

"We would like to thank Mónica Giménez for her work in editing the manuscript. The grant PI17/00198, funded by Instituto de Salud Carlos III (ISCIII) and co‐funded by the European Union, supported this study with also a grant provided by Novartis. Ana M. Giménez‐Arnau: Medical Advisor for Uriach Pharma/Neucor, Genentech, Novartis, FAES, GSK, Sanofi–Regeneron, Amgen, Thermo Fisher Scientific, Almirall, Celldex, Leo Pharma Research Grants supported by Uriach Pharma, Novartis, Grants from Instituto Carlos III‐FEDER Educational activities for Uriach Pharma, Novartis, Genentech, Menarini, LEO‐PHARMA, GSK, MSD, Almirall, Sanofi, Avene. Bruno Cenni and Barbara Ambros are Novartis employees. The rest of authors declare that there is no conflict of interest concerning the present work."